AxCellerate supports neurological drug development with human-relevant Brain-on-Chip models for preclinical testing, disease modelling and translational research.
Neurological drug development is one of the most complex and challenging areas of pharmaceutical research. The biology of the human nervous system is difficult to reproduce, and conventional preclinical models often provide only a partial view of how a candidate compound may behave in humans.
This can create uncertainty in early development, especially when teams need to evaluate safety, toxicity, biological response, target relevance or potential efficacy in disease-related contexts.
AxCellerate supports neurological drug development through advanced Brain-on-Chip technology and three-dimensional human-derived neuronal models. Our platform is designed to provide more human-relevant preclinical evidence, helping research teams investigate complex neurological mechanisms and make better-informed decisions before advancing their programs.
AxCellerate’s Brain-on-Chip platform combines human-derived neuronal models, microtechnology and functional readouts to support key questions in neuroscience drug development.
The technology can help R&D teams by providing:
Three-dimensional human-derived neuronal systems help bridge the gap between conventional in vitro models, animal studies and human biology.
Electrophysiological recording capabilities allow the observation of neuronal activity and network response, supporting a deeper understanding of compound effects.
Candidate compounds can be assessed in a more relevant preclinical environment to identify potential biological responses, safety signals or neurotoxic effects earlier in the development process.
When a suitable model is available, AxCellerate can support the study of disease mechanisms and efficacy-related responses in neurological research programs.
Potential therapeutic targets can be investigated in a three-dimensional neuronal context, helping teams assess biological relevance before further development.
The platform is designed to generate data that can strengthen the connection between preclinical research and human-relevant biological outcomes.
Advantages
For organizations working on CNS-related therapies, AxCellerate offers a preclinical approach designed to improve the quality and relevance of early evidence.
By integrating AxCellerate’s Brain-on-Chip platform into preclinical workflows, research teams can gain a clearer view of compound behaviour, disease-related mechanisms and potential development risks.
